Compare SCII & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCII | NBP |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.5M | 212.8M |
| IPO Year | 2025 | 2019 |
| Metric | SCII | NBP |
|---|---|---|
| Price | $10.14 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 18.3K | ★ 258.7K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $1.46 |
| 52 Week High | $10.14 | $5.19 |
| Indicator | SCII | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 44.52 |
| Support Level | $9.95 | $1.67 |
| Resistance Level | N/A | $1.98 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 100.00 | 15.87 |
SC II Acquisition Corp is a blank check company. The company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.